S
Shahab Asgharzadeh
Researcher at Children's Hospital Los Angeles
Publications - 107
Citations - 7169
Shahab Asgharzadeh is an academic researcher from Children's Hospital Los Angeles. The author has contributed to research in topics: Neuroblastoma & Internal medicine. The author has an hindex of 39, co-authored 92 publications receiving 5778 citations. Previous affiliations of Shahab Asgharzadeh include Northwestern University & University of Southern California.
Papers
More filters
Journal ArticleDOI
The genetic landscape of high-risk neuroblastoma
Trevor J. Pugh,Olena Morozova,Edward F. Attiyeh,Edward F. Attiyeh,Shahab Asgharzadeh,Shahab Asgharzadeh,Jun S. Wei,Daniel Auclair,Scott L. Carter,Kristian Cibulskis,Megan Hanna,Megan Hanna,Adam Kiezun,Jaegil Kim,Michael S. Lawrence,Lee Lichenstein,Aaron McKenna,Chandra Sekhar Pedamallu,Chandra Sekhar Pedamallu,Alex H. Ramos,Alex H. Ramos,Erica Shefler,Andrey Sivachenko,Carrie Sougnez,Chip Stewart,Adrian Ally,Inanc Birol,Readman Chiu,Richard Corbett,Martin Hirst,Shaun D. Jackman,Baljit Kamoh,Alireza Hadj Khodabakshi,Martin Krzywinski,Allan Lo,Richard A. Moore,Karen Mungall,Jenny Q. Qian,Angela Tam,Nina Thiessen,Yongjun Zhao,Kristina A. Cole,Kristina A. Cole,Maura Diamond,Maura Diamond,Sharon J. Diskin,Sharon J. Diskin,Yael P. Mosse,Yael P. Mosse,Andrew Wood,Andrew Wood,Lingyun Ji,Lingyun Ji,Richard Sposto,Richard Sposto,Thomas C. Badgett,Wendy B. London,Yvonne Moyer,Yvonne Moyer,Julie M. Gastier-Foster,Julie M. Gastier-Foster,Malcolm A. Smith,Jaime M. Guidry Auvil,Daniela S. Gerhard,Michael D. Hogarty,Michael D. Hogarty,Steven J.M. Jones,Eric S. Lander,Stacey Gabriel,Gad Getz,Robert C. Seeger,Robert C. Seeger,Javed Khan,Marco A. Marra,Matthew Meyerson,Matthew Meyerson,John M. Maris +76 more
TL;DR: The authors reported a low median exonic mutation frequency of 0.60 per Mb (0.48 nonsilent) and notably few recurrently mutated genes in high-risk neuroblastoma.
Journal ArticleDOI
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Thomas F. Eleveld,Derek A. Oldridge,Virginie Bernard,Jan Koster,Leo Colmet Daage,Sharon J. Diskin,Linda Schild,Nadia Bessoltane Bentahar,Angela Bellini,Mathieu Chicard,Eve Lapouble,Valérie Combaret,Patricia Legoix-Né,Jean Michon,Trevor J. Pugh,Lori S. Hart,JulieAnn Rader,Edward F. Attiyeh,Jun S. Wei,Shile Zhang,Arlene Naranjo,Julie M. Gastier-Foster,Michael D. Hogarty,Shahab Asgharzadeh,Malcolm A. Smith,Jaime M. Guidry Auvil,Thomas B.K. Watkins,Danny A. Zwijnenburg,Marli E. Ebus,Peter van Sluis,Anne Hakkert,Esther M. van Wezel,C. Ellen van der Schoot,Ellen M. Westerhout,Johannes H. Schulte,Godelieve A.M. Tytgat,M. Emmy M. Dolman,Isabelle Janoueix-Lerosey,Daniela S Gerhard,Huib N. Caron,Olivier Delattre,Javed Khan,Rogier Versteeg,Gudrun Schleiermacher,Jan J. Molenaar,John M. Maris +45 more
TL;DR: It is shown that RAS-MAPK pathway mutations may function as a biomarker for new therapeutic approaches to refractory disease and provide a rationale for genetic characterization of relapse neuroblastomas.
Journal ArticleDOI
Comparison of RNA-seq and microarray-based models for clinical endpoint prediction.
Wenqian Zhang,Ying Yu,Falk Hertwig,Falk Hertwig,Jean Thierry-Mieg,Wenwei Zhang,Danielle Thierry-Mieg,Jian Wang,Cesare Furlanello,Viswanath Devanarayan,Jie Cheng,Youping Deng,Barbara Hero,Huixiao Hong,Meiwen Jia,Li Li,Simon Lin,Yuri Nikolsky,André Oberthuer,Tao Qing,Zhenqiang Su,Ruth Volland,Charles Wang,May D. Wang,Junmei Ai,Davide Albanese,Shahab Asgharzadeh,Smadar Avigad,Wenjun Bao,Marina Bessarabova,Murray H. Brilliant,Benedikt Brors,Marco Chierici,Tzu-Ming Chu,Jibin Zhang,Richard Grundy,Min Max He,Scott J. Hebbring,Howard L. Kaufman,Samir Lababidi,Lee Lancashire,Yan Li,Xin X. Lu,Heng Luo,Heng Luo,Xiwen Ma,Baitang Ning,Rosa Noguera,Martin Peifer,John H. Phan,Frederik Roels,Frederik Roels,Carolina Rosswog,Susan Shao,Jie Shen,Jessica Theissen,Gian Paolo Tonini,Jo Vandesompele,Po-Yen Wu,Wenzhong Xiao,Joshua Xu,Weihong Xu,Jiekun Xuan,Yong Yang,Zhan Ye,Zirui Dong,Ke Zhang,Ye Yin,Chen Zhao,Yuanting Zheng,Russell D. Wolfinger,Tieliu Shi,Linda H. Malkas,Frank Berthold,Frank Berthold,Jun Wang,Weida Tong,Leming Shi,Leming Shi,Zhiyu Peng,Matthias Fischer,Matthias Fischer +81 more
TL;DR: It is demonstrated thatRNA-seq outperforms microarrays in determining the transcriptomic characteristics of cancer, while RNA-seq and microarray-based models perform similarly in clinical endpoint prediction.
Journal ArticleDOI
Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy
Kishore B. Challagundla,Petra Wise,Paolo Neviani,Haritha Chava,Mariam Murtadha,Tong Xu,Rebekah J. Kennedy,Cristina Ivan,Xinna Zhang,Ivan Vannini,Francesca Fanini,Dino Amadori,George A. Calin,Michael D. Hadjidaniel,Hiroyuki Shimada,Ambrose Jong,Robert C. Seeger,Shahab Asgharzadeh,Amir Goldkorn,Muller Fabbri +19 more
TL;DR: Data indicate a unique role of exosomic miR-21 andmiR-155 in the cross-talk between NBL cells and human monocytes in the resistance to chemotherapy, through a novel exosomal miR -21/TLR8-NF-кB/exosomicMiR- 155/TERF1 signaling pathway.
Journal ArticleDOI
Chromosome 6p22 Locus Associated with Clinically Aggressive Neuroblastoma
John M. Maris,Yael P. Mosse,Jonathan P. Bradfield,Cuiping Hou,Stefano Monni,Richard H Scott,Shahab Asgharzadeh,Edward F. Attiyeh,Sharon J. Diskin,Marci Laudenslager,Cynthia Winter,Kristina A. Cole,Joseph T. Glessner,Cecilia Kim,Edward C. Frackelton,Tracy Casalunovo,Andrew W. Eckert,Mario Capasso,Eric F. Rappaport,Carmel McConville,Wendy B. London,Robert C. Seeger,Nazneen Rahman,Marcella Devoto,Struan F.A. Grant,Hongzhe Li,Hakon Hakonarson +26 more
TL;DR: A common genetic variation at chromosome band 6p22 is associated with susceptibility to neuroblastoma and homozygosity for the at-risk G allele of the most significantly associated SNP, rs6939340, resulted in an increased likelihood of the development of Neuroblastoma.